Expression of oncogenic molecules in primary central nervous system lymphomas in immunocompetent patients

Acta Neuropathol. 1998 May;95(5):505-10. doi: 10.1007/s004010050831.

Abstract

We studied overexpression of p53, Bcl-2, Bcl-6, c-Myc and Mdm2 proteins by immunohistochemistry for a total of 27 primary central nervous system B cell lymphomas (CNS lymphomas) in immunocompetent patients and one CNS lymphoma in an AIDS patient. The expression of Epstein-Barr (EB) virus-encoded small RNA-1 (EBER-1) was also analysed using in situ hybridisation. Overexpression (more than 20% of cells stained) of p53 protein was detected in 8 of 27 immunocompetent cases (30%); 6 cases showed a nuclear stain and 2 cases showed cytoplasmic stain (nuclear exclusion). Strong Bcl-2 or Bcl-6 immunoreactivity suggestive of overexpression was seen, respectively, in 5 (19%) and 6 (22%) cases; 2 cases were positive for both immunoreactivities. Interestingly, overexpression of Bcl-2 or Bcl-6 was not seen in the cases which showed p53 overexpression (P < 0.03; chi-square test). EBER-1 expression was not detected in any of the 27 immunocompetent cases, but was found in the AIDS-related CNS lymphoma, which also showed an overexpression of Bcl-6, but not Bcl-2. None of the cases showed c-Myc or Mdm2 overexpression. Taken together, it is suggested that CNS lymphoma in immunocompetent hosts is a distinct disease that has a different molecular profile from those of systemic lymphoma and/or AIDS-related CNS lymphoma.

MeSH terms

  • Acquired Immunodeficiency Syndrome / metabolism
  • Adult
  • Aged
  • Aged, 80 and over
  • Central Nervous System Neoplasms / metabolism*
  • Female
  • Humans
  • Immunocompetence / physiology*
  • Immunohistochemistry
  • In Situ Hybridization
  • Lymphoma, B-Cell / metabolism*
  • Male
  • Middle Aged
  • Neoplasm Proteins / biosynthesis*

Substances

  • Neoplasm Proteins